Who We Are
About Us
Golden Orchid is dedicated to its mission to discover, develop, and commercialize immunotherapies that transform the treatment of challenging diseases, including cancer.
To fulfill its mission, the company is advancing several leading-edge proprietary technologies that are designed to initiate and sustain the immune system to mobilize and attack tumors. Collectively, Golden Orchid’s technologies are uniquely positioned to recruit and direct the immune system by activating cancer-fighting immune cells and inhibiting immune suppressive cells known to allow tumor growth.
Product candidates from Golden Orchid’s ANGX Pathway Activators and B-select monoclonal antibody technologies are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies (chemotherapy and radiation) as well as other cutting-edge immunotherapies. This diverse set of technologies has led to a strong pipeline of clinical and preclinical candidates, which are being evaluated in a number of cancer indications. Additionally, Golden Orchid’s technologies have the potential to generate product candidates that address other therapeutic areas, such as autoimmune and infectious diseases.
Golden Orchid collaborates and partners with leading academic investigators, along with pharmaceutical and biotechnology companies in an effort to develop its technologies in an expeditious manner and make new therapies available to patients in need.
Top Reasons Why Choose Us!
6
Years of Experience
25
EQUIPMENT
1052
Happy clients
24
Professional team
Professional Team
Alex Dillinger
Dr. Alex Dillinger is the Adele H. Lehman Professor of Microbiology and Immunobiology at Harvard Medical School. He has served as Chair of the Microbiology and Molecular Genetics Department since 1996, and he is a member of the National Academy of Sciences and the American Academy of Microbiology. His research investigates multiple facets of bacterial pathogenesis, with an emphasis on exploring virulence gene regulation and host-pathogen interactions. Recent awards include the Drexel Medicine Prize in Infectious Disease and the Sanofi-Institut Pasteur Award for Biomedical Research.
Barbara Santa Ph.D
Dr. Barbara is a professor of Microbiology and Immunobiology at Harvard Medical School. His laboratory focuses on understanding fundamental host-pathogen interactions that lead to virulence, and the development of protective immunity to intracellular pathogens. He serves as an editorial board member and reviewer for several prominent journals (Cell, Nature, PLoS Pathogens) and has led projects on antigen discovery and vaccine development for the New England Regional Center of Excellence for Biodefense and Emerging Infectious Diseases, Boston Children’s Hospital, and the Dana Farber Cancer Center. Dr. Barbara is an author on over 50 peer-reviewed articles, is an inventor on several patents and has received numerous awards and honors. He co-founded and served on the Scientific Advisory Board of Genocea Biosciences Inc...
Dave Willson
Dr. Dave Willson is a Professor at the University of California, Berkeley with joint appointments in the Divisions of Biochemistry
& Molecular Biology, Immunology and Pathogenesis, Infectious Diseases, and Microbial Biology. He holds the Edward E. Penhoet Distinguished Chair in Global Public Health and Infectious Diseases. Dr. Portnoy has focused his entire career of 30 years on the microbiology and immunology of Listeria monocytogenes. He is an expert on L. monocytogenes genetics, cell biology, and immunobiology and his lab was instrumental
in the development of
L. monocytogenes as a vector for cancer vaccines. He is an author on over 100 peer-reviewed articles in the areas of microbial pathogenesis, has served on the editorial board for numerous peer-reviewed journals and has received numerous awards and honors
in the fields of microbiology and immunology. In April 2013,
Dr. Portnoy was elected into the National Academy of Sciences